Xilis is developing microfluidic droplet-based patient-derived organoid (MDPDO) technology to guide precision therapy for cancer patients and accelerate drug discovery.
Employment range in NC
Primary site activity
All company activities
Products under development
XilisμO platform enables rapid diagnostics, personalized drug screening, and scalable patient-derived models for high-throughput drug discovery.